Eisenmenger syndrome

Eisenmenger syndrome
Field	Cardiology, Pulmonology

Eisenmenger syndrome. It is a severe, progressive medical condition characterized by the reversal of a congenital heart defect-induced left-to-right shunt into a right-to-left shunt due to the development of high pulmonary vascular resistance and pulmonary arterial hypertension. This pathophysiological shift leads to cyanosis, erythrocytosis, and multi-organ complications. The syndrome represents the most advanced form of pulmonary vascular disease associated with uncorrected cardiac defects, such as a ventricular septal defect, atrial septal defect, or patent ductus arteriosus.

Pathophysiology

The syndrome originates from a significant, uncorrected congenital heart defect that allows blood to flow from the systemic left ventricle or aorta to the pulmonary circulation. This chronic left-to-right shunt volume overloads the pulmonary arteries, leading to endothelial injury and vascular remodeling. Over time, this process causes obliterative pulmonary vasculopathy, dramatically increasing pulmonary vascular resistance. When this resistance surpasses systemic vascular resistance, the shunt reverses direction, creating a right-to-left shunt. This results in deoxygenated blood bypassing the lungs and entering the systemic circulation, a state known as cyanotic heart disease. The work of Paul Wood at the National Heart Hospital was instrumental in elucidating this hemodynamic progression.

Signs and symptoms

The hallmark sign is central cyanosis, often accompanied by clubbing of the fingers and toes. Patients may experience severe exertional dyspnea, syncope, and hemoptysis due to pulmonary vascular complications. Erythrocytosis develops as a compensatory mechanism for chronic hypoxemia, increasing the risk of hyperviscosity syndrome with symptoms like headache, dizziness, and visual disturbances. Other complications include stroke from paradoxical emboli, gout from increased urate production, and congestive hepatopathy. Squatting is a classic physical maneuver seen in some patients to relieve dyspnea.

Diagnosis

Diagnosis involves a combination of clinical assessment and advanced imaging. Echocardiography is the primary tool for identifying the underlying cardiac defect and assessing pulmonary artery pressure. Cardiac catheterization, performed at centers like the Mayo Clinic or Cleveland Clinic, remains the gold standard for directly measuring pulmonary vascular resistance and confirming shunt reversal. Magnetic resonance imaging of the heart provides detailed anatomical and functional data. Laboratory findings typically show marked polycythemia on a complete blood count and elevated uric acid levels. Electrocardiography often reveals signs of right ventricular hypertrophy.

Management

Management is complex and focuses on palliation, as the vascular changes are largely irreversible. It is led by specialized teams at institutions such as the Royal Brompton Hospital. Supportive therapy includes cautious phlebotomy for symptomatic hyperviscosity and supplemental oxygen. Pulmonary vasodilator therapies, including endothelin receptor antagonists like bosentan, phosphodiesterase type 5 inhibitors like sildenafil, and prostacyclin analogues, are central to modern care. Anticoagulation with warfarin is controversial due to bleeding risks. Heart-lung transplantation remains the definitive treatment for eligible patients. Patients must avoid dehydration, high altitudes, and certain anesthetic agents.

Prognosis

The prognosis has improved with advanced medical therapies but remains guarded. Survival into the third or fourth decade is now common, though mortality is significantly higher than in the general population. Major causes of death include sudden cardiac death, progressive heart failure, massive hemoptysis, and complications following non-cardiac surgery. Pregnancy carries an exceptionally high risk of maternal and fetal mortality and is generally contraindicated. The advent of targeted pulmonary hypertension therapy has positively altered the natural history, as evidenced by research from the University of California, San Francisco.

Epidemiology

The syndrome is a rare complication of congenital heart disease. Its incidence has declined in nations with advanced pediatric cardiology services due to early detection and repair of cardiac defects. It is more frequently observed in regions with limited access to cardiac surgery, such as parts of South Asia and Africa. The condition affects males and females equally. The historical shift in prevalence was documented in landmark studies from Boston Children's Hospital and the German Heart Centre Munich.

Category:Congenital heart defects Category:Pulmonary hypertension